Biocon’s new CEO Tambe sharpens focus on core therapies, global mkts

Bengaluru: As Biocon prepares for a leadership transition on April 1, newly designated CEO and MD Shreehas Tambe has outlined a strategic reset to transform the company into a fully integrated global medicines player. Tambe becomes the first CEO of Biocon following the complete integration of Biocon Biologics as its wholly owned subsidiary. He earlier led Biocon Biologics as CEO and MD, building it into a top-five global biosimilars player and taking revenues past $1 billion in 2024.A key pillar of the strategy is a sharper focus on diabetes, oncology and immunology, where the company plans to deepen capabilities and scale rather than pursue broad-based expansion. This marks a shift from a volume-driven generics model to a more science-led, value-driven approach aimed at improving outcomes and margins.Geographically, Biocon is adopting a dual-market strategy. In India, the company will continue to rely on partnerships, including its tie-up with Eris Life Sciences for insulin and oncology products. For newer segments such as peptides, it will evaluate additional partnerships or alternative go-to-market models.In contrast, the United States and other global markets will be central to the company’s next phase of growth. Biocon is shifting towards a more patient-centric commercial model—engaging directly with payers, enabling mail-order delivery and supplying directly to pharmacies. Partnerships such as Civica Rx reflect this move to improve access and reduce dependence on intermediaries.Alongside growth, the company is strengthening its balance sheet. Over the past 6–8 months, it has raised nearly Rs 10,000 crore in two tranches, using the proceeds to retire high-cost debt and simplify its structure. This has brought down its net debt-to-EBITDA ratio from 4.3 to around 2.5, with further deleveraging expected through improved operating cash flows.Biocon Biologics has also restructured $1.1 billion of debt linked to the Viatris acquisition and has ownership of key biosimilars assets along with rights to immunology products such as adalimumab and etanercept.Beyond these priorities, the company’s broader transformation includes building an office of AI (augmented intelligence) to enhance decision-making and execution, while rethinking patient access through direct engagement models.Biocon is also positioning itself for emerging opportunities in obesity and peptide-based therapies, leveraging its strengths in insulin, peptide manufacturing and drug delivery devices. In biosimilars, it plans to deepen its portfolio and explore adjacencies such as antibody drug conjugates (ADCs), strengthening its oncology pipeline as it pivots towards a capability-led growth model.